Harmony Biosciences Announces Pricing Of Upsized Initial Public Offering
PLYMOUTH MEETING, Pa. and CHICAGO, Aug. 18, 2020 /PRNewswire/ — Harmony Biosciences Holdings, Inc., a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, announced today the pricing of its upsized initial public offering of 5,348,837 shares of common stock at a price to the public of $24.00 per share. […]
